Expression in situ of the recombinant human erythropoetin and recombinant insulin.

Authors

• Michael V. Tyurin CEO, Executive Chairman, President of Microbial Biocatalyst International, Inc. and Inorgcarbdiesel, Inc., Houston, TEXAS 77230.

Abstract

Our aim was to check the suitability of the human intestine for the delivery of the re-combinant proteins in humans. The prospective applications of said technology are huge, since travel in the outer Space to locate new planets for the relocation of the over crowded Earth will face the need for the crew vaccination from the pathological microorganisms, found in these outer Space locations. We invented the technology to treat Diabetes II and his chronic anemia in the adult volunteer as the draft of said new applications of said in vivo technology of the recombinant proteins delivery in humans. The strain of lactobacilli from the normal human intestinal microflora was isolated, genetically engineered and then returned back for the adhesion back to the host intestinal epithelium of the volunteer. The volunteer was cured from his Diabetes II and chronic anemia symptoms. We discuss the potential applications of said technology for the in vivo expression of the vaccines for the crews of the outer space long range travel missions coming soon.